Abstract
Schwartz-Jampel syndrome (SJS) type 1 (OMIM; #255800), a rare cause of skeletal dysplasia, is characterized by myotonic myopathy, chondrodystrophy, short stature, facial and eye abnormalities. SJS type 1 develops due to variations in the HSPG2 gene which produces the “perlecan” molecule, one of the main proteoglycans of the basement membrane. A 6-year-old girl presented with short stature, a mask face, shrunken lips, narrow palpebral opening due to blepharospasm, stiffness of facial muscles, micrognathia, overlapping teeth, a short neck, and a bell-shaped thorax due to myotonic myopathy. She was diagnosed with SJS type 1 due to compound heterozygosity of two novel variations in the HSPG2 gene. In patients with short stature and an accompanying myotonic myopathy SJS should be considered. Compound heterozygosity may cause typical clinical findings of SJS. In case of suspicion creatinine kinase levels can be measured, and the determination of myotonia may require evaluation with electromyography. Once the diagnosis is made, patients should be carefully monitored in terms of growth, neuromuscular disorders, joints problems and bone health.
Keywords: HSPG2 gene, myotonia, short stature, skeletal dysplasia
Read the full text
4 sections · 1 figure · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Online Mendelian Inheritance in Man, OMIM®. Cassandra L. Kniffin (12/15/2006). World Wide Web URL: https://omim.org/
Dave M, Lavanya SR, Khamesra R, Bapat P, Prasath A. Schwartz Jampel syndrome (SJS)-one in a million syndrome. J Assoc Physicians India. 2020;68:89-90.
Giedion A, Boltshauser E, Briner J, Eich G, Exner G, Fendel H, Kaufmann L, Steinmann B, Spranger J, Superti-Furga A. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. Eur J Pediatr. 1997;156:214-223.
Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, Beighton P, Hamida CB, Hammouda H, Cruaud C, White PS, Samson D, Urtizberea JA, Lehmann-Horn F, Weissenbach J, Hentati F, Fontaine B. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000;26:480-483.
Kulkarni ML, Pillai R. Schwartz-Jampel syndrome. Indian Pediatr. 2004;41:285.
Basiri K, Fatehi F, Katirji B. The Schwartz-Jampel syndrome: case report and review of literature. Adv Biomed Res. 2015;4:163.
Van Meir N, De Smet L. Carpal tunnel syndrome in children. J Pediatr Orthop B. 2005;14:42-45.
Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A comprehensive online calculator for pediatric endocrinologists: ÇEDD çözüm/TPEDS metrics. J Clin Res Pediatr Endocrinol. 2017;9:182-184. Epub 2017 Apr 26
Bundak R, Bas F, Furman A, Günöz H, Darendeliler F, Saka N, Poyrazoğlu S, Neyzi O. Sitting height and sitting height/height ratio references for Turkish children. Eur J Pediatr. 2014;173:861-869. Epub 2014 Jan 9
Aberfeld DC, Hinterbuchner LP, Schneider M. Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain. 1965;88:313-322.
Schwartz O, Jampel RS. Congenital blepharophimosis associated with a unique generalized myopathy. Arch Ophthalmol. 1962;68:52-57.
Huttenlocher PR, Landwirth J, Hanson V, Gallagher BB, Bensch K. Osteo-chondro-muscular dystrophy. A disorder manifested by multiple skeletal deformities, myotonia, and dystrophic changes in muscle. Pediatrics. 1969;44:945-958.
van Huffelen AC, Gabreĕls FJ, Luypen-vd Horst JS, Slooff JL, Stadhouders AM, Korten JJ. Chondrodystrophic myotonia. A report of two unrelated Dutch patients. Neuropadiatrie. 1974;5:71-90.
Pavone L, Mollica F, Grasso A, Cao A, Gullotta F. Schwartz-Jampel syndrome in two daughters of first cousins. J Neurol Neurosurg Psychiatry. 1978;41:161-169.
Moodley M, Moosa A. Chondrodystrophic myotonia (Schwartz-Jampel syndrome) in South African children. Neuropediatrics. 1990;21:206-210.
Pinto-Escalante D, Ceballos-Quintal JM, Canto-Herrera J. Identical twins with the classical form of Schwartz-Jampel syndrome. Clin Dysmorphol. 1997;6:45-49.
Spranger J, Hall BD, Häne B, Srivastava A, Stevenson RE. Spectrum of Schwartz-Jampel syndrome includes micromelic chondrodysplasia, kyphomelic dysplasia, and Burton disease. Am J Med Genet. 2000;94:287-295.
Yan W, Dai J, Shi D, Xu X, Han X, Xu Z, Chen D, Teng H, Jiang Q. Novel HSPG2 mutations causing Schwartz‑Jampel syndrome type 1 in a Chinese family: A case report. Mol Med Rep. 2018;18:1761-1765. Epub 2018 Jun 6
Ho NC, Sandusky S, Madike V, Francomano CA, Dalakas MC. Clinico-pathogenetic findings and management of chondrodystrophic myotonia (Schwartz-Jampel syndrome): a case report. BMC Neurol. 2003;3:3. Epub 2003 Jul 2
French MM, Smith SE, Akanbi K, Sanford T, Hecht J, Farach-Carson MC, Carson DD. Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol. 1999;145:1103-1115.
Schofield KP, Gallagher JT, David G. Expression of proteoglycan core proteins in human bone marrow stroma. Biochem J. 1999;343:663-668.
Brown AJ, Alicknavitch M, D’Souza SS, Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD, Farach-Carson MC. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone. 2008;43:689-699. Epub 2008 Jun 6.
Gubbiotti MA, Neill T, Iozzo RV. A current view of perlecan in physiology and pathology: a mosaic of functions. Matrix Biol. 2017;57-58:285-298. Epub 2016 Sep 6
Arikawa-Hirasawa E. Impact of the heparan sulfate proteoglycan perlecan on human disease and health. Am J Physiol Cell Physiol. 2022;322:C1117-C1122. Epub 2022 Apr 13


